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Purpose: To investigate the effect of cisplatin on cell toxicity and metastasis through modulation of KAI1 
gene expression. 
Methods:  MCF-7cells were incubated with different concentrations of cisplatin for 24 h. RNA was 
extracted by trizol and cDNA synthesized. KAI1 and TBP were chosen as target and internal control 
genes, respectively. Specific primers were designed by primer express software, v.3.0. KAI1/TBP and 
gene expression ratio was calculated using the formula, 2 -∆∆Ct. 
Results: Cisplatin exerted a dose-dependent inhibitory effect on the viability of highly metastatic MCF-7 
cells. KAI1/TBP gene expression ratios were 1.97 ± 0.19 (p < 0.05), 2.96 ± 0.55 (p < 0.05), 9.06 ± 0.27 
(p < 0.001) and 12.38 ± 0.88 (p < 0.01) in 10, 20, 50 and 100 µM concentrations of cisplatin. 
Conclusion: These findings indicate that cisplatin can inhibit metastasis by up-regulating KAI1 gene in 
MCF-7cells. 
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INTRODUCTION 
 
Cancer is one of the highest causes of 
mortality in the world. The disease is 
attributed to various causes including 
mutagenesis and carcinogenic chemicals in 
the environment. Breast cancer accounts for 
10.4 % of all cancer types among women; it 
is the most common type of non-skin cancer 
in women and the fifth most common cause 
of cancer death [1]. 
 
The high morbidity and mortality associated 
with breast cancer derive from its metastasis 
to lungs, bone and liver [2]. Metastasis is the 
major cause of death in human cancer 
patients and involves several stages, 
including loss of intracellular adhesion in the 
primary tumor region, migration into 
lymphatic or blood vessels, adhesion to the 
surface of the luminal endothelium, and 
invasion of other organ tissues [3].   
 
Cisplatin (cis-diamminedichloroplatinum or 
cis-DDP/CDDP) is an anti-cancer drug widely 
used in the treatment of various cancers, 
including breast, testicular, ovarian, cervical, 
prostate, head and neck, bladder, and lung 
cancers [4]. Cisplatin can cause DNA 
damage by forming drug-DNA adducts and 
lead to apoptosis and/or necrosis. It, 
however, can also bind to other cell 
components such as glutathione, 
phospholipids, phosphatidylserine, 
microfilaments, thiol-containing proteins or 
RNA to cause cell damage. Cisplatin-induced 
cell death has been linked with ceramide-, 
mitochondria- and death receptor-mediated 
apoptosis, depending on the cell type being 
tested [5].   
 
The KAI1 gene encodes an integral 
membrane protein that consists of four 
transmembrane domains and one large 
extracellular domain, which indicates that 
KAI1 protein is a member of the 
transmembrane 4 super family (TM4SF), also 
known as the tetraspanin superfamily [6]. 
KAI1 is involved in cell migration, adhesion 
and synapse formation [7]. Many reports 
have documented that the KAI1 gene 
suppresses metastasis in many types of 
human cancers including breast, pancreatic, 
lung, bladder, hepatic, gastric, breast, 
colorectal, ovarian, esophageal, cervical and 
endometrial [8,9]. 
 
The aim of the current study was to 
investigate the effect of cisplatin on cell 
toxicity and metastasis through modulation of 




Cell culture and cisplatin treatment 
 
MCF-7, a human breast adenocarcinoma cell 
line was obtained from National Cell Bank of 
Iran (NCBI), Pasteur Institute of Iran (NCBI, 
C135). MCF-7cells were cultured in RPMI-
1640 medium containing 10 % fetal bovine 
serum and 1 % penicillin–streptomycin under 
standard culture conditions (37 °C, 95 % 
humidified air and 5 % CO2). The cells were 
incubated with different concentrations of 
cisplatin (0, 10, 20, 40, 80 and 100 µM) at 24 
h. Each concentration of cisplatin was tested 
on 3 wells of the 96-well plates containing 
1×104 MCF-7cells. In each experiment, three 
MCF-7 cultured wells with no drug incubation 
were used as negative controls [10]. 
 
MTT assay and LC50 determination 
 
MTT solution (10 µl, 5 mg/ml in phosphate 
buffered saline, PBS) was added to the cell 
monolayer in each well of a 96-well plate. 
The cells were incubated in a humidified 
incubator at 37 ºC for 3 h. The assay is 
based on the capacity of mitochondrial 
dehydrogenase enzymes in living cells to 
convert the yellow water-soluble substrate, 3-
(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl 
tetrazolium bromide (MTT), into a dark blue 
formazan product which is insoluble in water. 
The insoluble formazan was dissolved in a 
solution containing 100 µl isopropanol and its 
optical density (OD) was read against a blank 
reagent with an ELISA reader at a 
wavelength of 570 nm. The 50 % lethal 
Mokhtari et al 
Trop J Pharm Res, August 2012;11 (4): 525 
concentration (LC50) value of cisplatin on 
MCF-7 cells at 24 h was calculated. LC50 was 
determined by probit analysis using Pharm 
PCS (Pharmacologic Calculation System) 
statistical package (Springer Verlag, USA) 
[10]. 
 
Total RNA extraction 
 
MCF-7 cells were rinsed with cold PBS. 
Thereafter, 2 ml of trizol (Invitrogen, USA) 
was added and incubated at room 
temperature for 5 min to lyse the cells in a 
culture dish. Afterward, 400 µl of chloroform 
was added and the mixture incubated at 
room temperature for 3 min. The mixture was 
centrifuged at 12000 g (4 °C) for 15 min. The 
upper phase was transferred to a fresh 
Eppendorf tube and 500 µl of isopropanol 
added to the mixture. After incubation on ice 
for 10 min, the sample was centrifuged at 
12000 g (4 °C) for 15 min. Ethanol (75 %, 70 
µl) was added to the RNA pellets and the 
mixture was centrifuged at 7500 g (4 °C) for 5 
min. The RNA pellets were dissolved in 
diethyl pyro carbonate (DEPC)-treated water. 
Finally, the concentration and purity of the 
isolated RNA were measured using a 
photonanometer (IMPLEN, Germany) at 230, 
260 and 280 nm. RNA samples with the 
A260/A230 and A260/A280 ratios greater 




cDNA synthesis was performed using 1st 
strand cDNA synthesis kit (Roche, Germany) 
in 20 µl reaction mixture containing 3 ml of 
total RNA (1 µg), 2 µl reaction buffer 10x, 4 µl 
MgCl2 (25mM), 2 µl deoxynucleotide mix 
(1mM), 2 µl oligo-p(dT)15 primer (0.04 A260 
units, 1.6 µg), 1 µl RNase inhibitor (50 units), 
0.8 µl AMV reverse transcriptase (20 units) 
and 7.2 µl distilled water. Thermal cycling 
was performed in the ABI 2720 Thermal 
Cycler (Applied Biosystems, Foster City, CA, 
USA) for 10 min at 25 °C, for 60 min at 42 °C 
(cDNA synthesis) followed by 5 min at 95 ºC 
(reverse transcriptase inactivation) and then 
cooled to 4 ºC for 5 min. 
Agarose gel electrophoresis 
 
The PCR products were resolved by 
electrophoresis in 1.5 % agarose gel in 0.5X 
TBE (Tris-borate-EDTA) buffer. 100 bp ladder 
was used as molecular weight marker. After 
staining the gel with ethidium bromide, 
fragments were visualized by UV 
transilluminator (Biorad Gel Doc XR, UK) and 
photographed. Gel electophoresis (Payapa-
johesh Electrophoresis, Iran) was carried out 
to confirm the primers’ specificity and 




In this study, KAI1 gene located on 
chromosome 11 (11p11.2) and TBP gene 
located on chromosome 6 (6q27), were 
selected as target and reference genes, 
respectively. Primers were designed using 
primer express software, v.3.0 (Applied 
Biosystems, USA). Synthesis of these 
primers was performed by Bioneer, South 
Korea. The sequence of the PCR forward 
primer for KAI1 gene was 5' 
GTCACTATGCTCATGGGCTTCC3' and that 
of reverse primer was 5' 
GAGGATCAGGAGCAGGAAAGC3'. The 
sequence of the forward primer for 
housekeeping gene TBP was 5' 
AATCATGAGGATAAGAGAGCCACG3' and 
that of reverse primer was 5' 
AGTCTGGACTGTTCTTCACTCTTGG3'. 
Primer specificity was tested using BLAST 




Power SYBR Green PCR Master Mix 
(Applied Biosystems, Warrington, UK) was 
employed to perform quantitative PCR on ABI 
7300 Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA), applying 
the following thermal-cycling conditions: 10 
min at 95 ˚C (1 repeat) as first denaturation 
and Hot-start enzyme activation, followed by 
40 cycles at 95 ˚C for 15 s and 60 ˚C for 1 
min. Each complete amplification stage was 
followed by a melting stage; at 95 ˚C for 15 s, 
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60 ˚C for 30 s and 95 ˚C for 15 s. PCR 
amplification was performed in 25 µl reaction 
mixture containing 12.5 µl Power SYBR 
Green PCR Master Mix (2x), 1 µl Forward 
primer (0.4µM), 1 µl Reverse primer (0.4µM), 
5 µl first-strand cDNA (100 ng) and 5.5 µl 
double-distilled water. Standard curve was 
obtained by plotting Ct values against log 
cDNA concentrations of five serial two-fold 
dilutions of the target nucleic acid. The serial 
dilutions were 37.5, 75, 150, 300 and 600 
ng/µl of standard cDNA used. It was used to 
determine the dynamic range of the target 
and reference genes, to calculate the slope 
(PCR efficiency), R2 (correlation coefficient), 
precision (standard deviation) and sensitivity 
(y-intercept). The efficiency of the reaction 
was calculated using Eq 1 [11].   
E = [10(-1/slope) –1]     …………… (1) 
 
Quantitative data analysis of Real-time 
PCR 
 
Calculation of the gene expression was 
carried out using comparative threshold cycle 
(Ct). The mean threshold cycle (mCt) was 
obtained from triplicate amplifications during 
the exponential phase. Thereafter, mCt value 
of reference gene (TBP) was subtracted from 
mCt value of the target gene (KAI1 gene) to 
obtain ∆Ct and ∆∆Ct values of each sample 
were calculated from corresponding Ct 
values; where ∆∆Ct = [mCt target - mCt 
reference] (untreated sample) - [mCt target - mCt 
reference](treated sample). Finally, KAI1 gene 
expression/TBP gene expression ratio was 
calculated using Eq 2 [12]. 
Ratio = 2 -∆∆Ct)     ………. (2) 
 
Statistical analysis  
 
Data are expressed as mean ± standard 
deviation, correlation coefficients (R2) and 
assay reproducibility, and were processed 
using Microsoft Office Excel 2007 software. 
P-value of < 0.05 was considered statistically 





Cisplatin cytotoxicity on MCF-7cells 
Various concentrations of cisplatin (0, 10, 20, 
50 and 100µM) at 24 h were cytotoxic to 
breast cancer cells (MCF-7cell line). At 
concentrations of 10, 20, 40, 80 and 100 µM 
of cisplatin MCF-7cell viability was reduced to 
84.0 ± 12.4  (statistically insignificant, p > 
0.05), 67.2 ± 12.4  (p < 0.05), 35.6 ± 3.4 (p 
<0.001) and 30.7 ± 2.5 % (p < 0.001), 
respectively. LC50 of cisplatin after 24 h was 
143.4 ± 14.6 µg/ml, as reported in our 
previous study [10]. 
 
Absolute quantification analysis and PCR 
efficiency 
We used different concentrations of cDNA for 
KAI1 and TBP genes to prepare standard 
curves. The dynamic ranges of KAI1 and 
TBP genes were obtained from 75 to 600 
ng/µl. The slope of the standard curves were 
-3.31 (KAI1) and -3.36 (TBP). PCR efficiency 
was was 92.30 % for KAI1 and 98.15 % for 
TBP (Figure 1). 
 
 
Figure 1: Standard curves for TBP (◊) and KAI1 
(●) genes. Standard curve was generated by 
plotting Ct values against the logarithm of the 
cDNA concentration; for TBP, slope = -3.36, y-
intercept = 33.649, R2= 0.999.;for KAI1, slope = -
3.52, y-intercept = 33.418, R2= 0.997 
 
Melting curve analysis and gel 
electrophoresis 
The melting curve was drawn based on the 
temperature (x-axis) and ∆Rn derivation (y-
axis). The reproducibility of a melting curve 
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was high with a standard deviation of only 
0.1oC between runs. It was generated to 
screen for primer dimers and to document 
single product formation for each gene. The 
melting peaks were drawn at 78.8 °C for TBP 
gene and 80.3 °C for KAI1 gene as shown in 
Figure 2. Gel electrophoresis results showed 




Figure 2: Specific melting curve analysis for TBP 
and KAI1 genes. The melting peaks at 78.8 °C for 
TBP gene (1) and 80.3 °C for KAI1 gene (2) 
indicate that the specific products melted at 
different temperatures. Flat peak demonstrates 
non-template control (3).  
 
Relative quantification analysis using 
amplification plots 
 
The relative gene expression between two 
samples (treated and untreated) can be 
determined by the difference in their Ct 
values of exponential phase. The mCt value 
for TBP gene was 23.8 at different 
concentrations of cisplatin (0, 10, 20, 50 and 
100µM). The values of mCts for KAI1 gene 
were 33.1, 32.2, 31.6, 30.0 and 29.5 at 0, 10, 
20, 50 and 100 µM concentrations of 
cisplatin, respectively. The m∆Ct value for 
untreated sample was scaled as 9.30. The 
m∆Ct values for treated samples of 10, 20, 
50 and 100 µM of cisplatin concentrations 
were scaled as 8.32, 7.73, 6.12 and 5.67. 
The ∆∆Ct values were scaled as -0.98, -1.57, 
-3.18 and -3.63 for 10, 20, 50 and 100 µM of 
cisplatin concentrations. The calculated 2 -∆∆Ct 
values were 1.97± 0.19 (p < 0.05), 2.96 ± 
0.55 (p < 0.05), 9.06 ± 0.27 (p < 0.001) and 
12.38 ± 0.88 (p < 0.01) for 10, 20, 50 and 100 




Figure 3: Photograph of a 1.5 % agarose gel 
showing TBP and KAI1 PCR products. Lane SM: = 
100 bp size marker; Lane 1 = 96 bp PCR product 
of TBP gene; Lane 2 = non template control; Lane 




Figure 4: Fold change in KAI1 gene expression. 
Note: Cisplatin imposed an increase in mRNA 
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DISCUSSION 
 
The development of cancer is multiphasic, 
multigenic and multifactorial. Therefore, the 
anticancer efficacy of an agent will more 
likely depend on the nature and number of 
cellular, biochemical and molecular events 
being modulated by the agent as well as it 
side effects.  
 
The most common sites of breast cancer 
metastasis are the lungs, bones, and liver 
[13]. Cisplatin is a first-line therapy for 
metastatic breast cancer. Cisplatin and 
gemcitabine have single-agent activity in 
metastatic breast cancer, and preclinical data 
support synergy of the combination [14]. 
Cisplatin is one of the major 
chemotherapeutic weapons used against 
different human cancers, although its 
mechanism of apoptosis induction is not fully 
understood. 
 
Most cancer deaths are due to the 
development of metastasis, hence the most 
important improvements in morbidity and 
mortality will result from prevention of such 
disseminated disease. Metastasis has been 
found to be accompanied by various 
physiological alterations involved in the 
degradation of extracellular matrix (ECM), 
which allow cancer cells to invade blood or 
lymphatic system to spread to other tissues 
or organs. Tumor cell invasion and 
metastasis is associated with down-
regulation of metastasis suppressor genes, 
the loss of function of which is an important 
event during the progression of a tumor cell 
from a non-metastatic to metastatic 
phenotype [15]. Several laboratories have 
identified more than 20 metastasis 
suppressors that inhibit metastasis without 
blocking tumor formation [16]. KAI1 protein 
was first identified as a metastasis 
suppressor in prostate cancer. It has been 
documented that progression of metastasis is 
associated with down-regulation of KAI1 [17]. 
Down-regulation of KAI1 gene in advanced 
cancers does not appear to involve mutations 
[18]. KAI1, like other TM4SF proteins, has 
been reported to interact with several 
integrins [19]. This association likely plays an 
important role in the function of KAI1-
mediated metastasis suppression [6]. KAI1 
acts as a modulator of the integrin 
downstream signals and down-regulates the 
formation of the p130CAS-Crk complex, 
leading to inhibition of cell migration [20]. We 
observed that cisplatin increased the 
expression of KAI1 gene in MCF-7 cells at 24 
h. These observations indicate that cisplatin 
can probably inhibit metastasis in breast 
cancer by inhibition of proliferation and 





For the first time, we showed in the present 
study that treatment with cisplatin for 24 h 
induces inhibition of proliferation of highly 
metastatic MCF-7 cells in a dose-dependent 
manner. Also, up-regulation of KAI1 mRNA 
levels were observed in MCF-7 cells, in a 
dose-dependent manner. These findings 
indicate that cisplatin probably inhibits 
metastasis in breast cancer by inhibition of 
proliferation and increased expression of 
KAI1 gene in MCF-7 cells. The results 
presented here warrant further investigation 
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